Metamizole – a well-known drug with an established position in the treatment of pain and fever – what do we know and what else should we learn? 5 facts you should know Review article
Article Sidebar
Published:
Mar 31, 2024
Keywords:
metamizole, pain, fever
Main Article Content
Abstract
In the pharmacotherapy of pain and fever, we should always choose pharmacotherapy contextually, both in relation to the symptoms and the patient’s characteristics. In practice, you cannot make a random choice of drug because there are no so-called class effect, which means that each drug is characterized by a unique pharmacokinetic and pharmacodynamic profile, and these features should be one of the most important elements of personalizing the choice of drug. One of the drugs used to treat pain and fever is metamizole. Its pharmacokinetic and pharmacodynamic profile and wide range of clinical applications enable personalization of pharmacotherapy.
Article Details
How to Cite
Woroń, J. (2024). Metamizole – a well-known drug with an established position in the treatment of pain and fever – what do we know and what else should we learn? 5 facts you should know. Medycyna Faktow (J EBM), 17(1(62), 73-76. https://doi.org/10.24292/01.MF.0124.11
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Miljković MN, Rančić NK, Simić RM et al. Metamizole: Current Status of the Safety and Efficacy. Hosp Pharm. 2018; 5: 694-704.
2. Andrade S, Bartels DB, Lange R et al. Safety of metamizole: a systematic review of the literature. J Clin Pharm Ther. 2016; 41: 459-77. http://doi.org/10.1111/jcpt.12422.
3. Kötter T, da Costa BR, Fässler M et al. Metamizole-associated adverse events: a systematic review and meta-analysis. PloS One. 2015; 10: e0122918. http://doi.org/10.1371/journal.pone.0122918.
4. Lutz M. Metamizole (Dipyrone) and the Liver: A Review of the Literature. J Clin Pharmacol. 2019; 59: 1433-42. http://doi.org/10.1002/jcph.15.
5. Gillmann HJ, Reichart J, Leffler A et al. The antipyretic effectiveness of dipyrone in the intensive care unit: A retrospective cohort study. PLoS One. 2022; 17(3): e0264440 http://doi.org/10.1371/journal.pone.0264440.
6. Klose S, Pflock R, König IR et al. Metamizole and the risk of drug-induced agranulocytosis and neutropenia in statutory health insurance data. Naunyn Schmiedebergs Arch Pharmacol. 2020; 393: 681-90. http://doi.org/10.1007/s00210-019-01774-4.
7.Hoffmann F, Bantel C, Jobski K. Agranulocytosis attributed to metamizole: An analysis of spontaneous reports in EudraVigilance 1985–2017. Basic Clin Pharmacol Toxicol. 2020; 126: 116-25. http://doi.org/10.1111/bcpt.13310 .
8. Stueber T, Vakulya B, Gillmann H-J et al. Die Anwendungspraxis von Metamizol und Paracetamol bei der antipyretischen Therapie auf Intensivstationen deutscher Universita¨tskliniken – eine webbasierte Umfrage. Ana¨sth Intensivmed. 2019; 60: 5-10.
9. Shear NH. Drug Eruption & Reaction Manual, CRC Press, Boca Raton 2020.
10. Tymiński R, Woroń J. Niekorzystne interakcje leków. Aspekty kliniczne i prawne. Medical Tribune Polska, Warszawa 2020.
11. Wiela-Hojeńska A, Jaźwińska-Tarnawska E, Hinneburg I et al. Niepożądane działania leków. MedPharm Polska, Wrocław 2019.
12. de Leeuw TG, Dirckx M, Gonzalez Candel A et al. The use of dipyrone (metamizole) as an analgesic in children: what is the evidence? A review Pediatric Anesth. 2017; 27: 1193-201.
13. Ziesenitz VC, Erb TO, Trachsel D et al. Safety of dipyrone (metamizole) in children-What’s the risk of agranulocytosis? Pediatric Anesthesia. 2018; 28(2): 186-7.
14. Stammschulte T, Ludwig WD, Mühlbauer B et al. Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990–2012. Eur J Clin Pharmacol. 2015; 71(9): 1129-38.
15. Metamizol (opis profesjonalny).
16. IASP. Pain.
17. Pharmindex. Metamizole sodium.
2. Andrade S, Bartels DB, Lange R et al. Safety of metamizole: a systematic review of the literature. J Clin Pharm Ther. 2016; 41: 459-77. http://doi.org/10.1111/jcpt.12422.
3. Kötter T, da Costa BR, Fässler M et al. Metamizole-associated adverse events: a systematic review and meta-analysis. PloS One. 2015; 10: e0122918. http://doi.org/10.1371/journal.pone.0122918.
4. Lutz M. Metamizole (Dipyrone) and the Liver: A Review of the Literature. J Clin Pharmacol. 2019; 59: 1433-42. http://doi.org/10.1002/jcph.15.
5. Gillmann HJ, Reichart J, Leffler A et al. The antipyretic effectiveness of dipyrone in the intensive care unit: A retrospective cohort study. PLoS One. 2022; 17(3): e0264440 http://doi.org/10.1371/journal.pone.0264440.
6. Klose S, Pflock R, König IR et al. Metamizole and the risk of drug-induced agranulocytosis and neutropenia in statutory health insurance data. Naunyn Schmiedebergs Arch Pharmacol. 2020; 393: 681-90. http://doi.org/10.1007/s00210-019-01774-4.
7.Hoffmann F, Bantel C, Jobski K. Agranulocytosis attributed to metamizole: An analysis of spontaneous reports in EudraVigilance 1985–2017. Basic Clin Pharmacol Toxicol. 2020; 126: 116-25. http://doi.org/10.1111/bcpt.13310 .
8. Stueber T, Vakulya B, Gillmann H-J et al. Die Anwendungspraxis von Metamizol und Paracetamol bei der antipyretischen Therapie auf Intensivstationen deutscher Universita¨tskliniken – eine webbasierte Umfrage. Ana¨sth Intensivmed. 2019; 60: 5-10.
9. Shear NH. Drug Eruption & Reaction Manual, CRC Press, Boca Raton 2020.
10. Tymiński R, Woroń J. Niekorzystne interakcje leków. Aspekty kliniczne i prawne. Medical Tribune Polska, Warszawa 2020.
11. Wiela-Hojeńska A, Jaźwińska-Tarnawska E, Hinneburg I et al. Niepożądane działania leków. MedPharm Polska, Wrocław 2019.
12. de Leeuw TG, Dirckx M, Gonzalez Candel A et al. The use of dipyrone (metamizole) as an analgesic in children: what is the evidence? A review Pediatric Anesth. 2017; 27: 1193-201.
13. Ziesenitz VC, Erb TO, Trachsel D et al. Safety of dipyrone (metamizole) in children-What’s the risk of agranulocytosis? Pediatric Anesthesia. 2018; 28(2): 186-7.
14. Stammschulte T, Ludwig WD, Mühlbauer B et al. Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990–2012. Eur J Clin Pharmacol. 2015; 71(9): 1129-38.
15. Metamizol (opis profesjonalny).
16. IASP. Pain.
17. Pharmindex. Metamizole sodium.